Immunocore Aims For $100m IPO After Immunotherapy Success

Proof-Of-Concept For TCR platform

The UK biotech is set for a NASDAQ launch which could propel it to its first commercial launch by 2022.

Nasdaq ipo
The UK-headquartered biotech is set to debut on the NASDAQ exchange shortly.

After many rocky years where it looked as though Immunocore might never realize its early promise, the UK biotech company is back on track, and expected to complete a $100m IPO within days.

The Oxford-headquartered firm was spun out from Medigene in 2008 with a focus on developing a new kind of immunotherapy,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip